Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK208141 (gD2t) vaccine for genital herpes prevention
NCT00699764Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 1996
- Primary completion
- Oct 1999
01
Overview
Phase 3, randomised, double-blind trial in genital herpes comparing GSK208141 with Placebo (2 arms). Primary endpoints: Unsolicited adverse experiences at 7 months and Acquisition of genital herpes disease in healthy female adults at 19 months. Started Mar 1996; status: completed.
02
Drugs
Simplirix
03
Conditions
genital herpes
Beyond the preview
Go deeper on NCT00699764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00699764.